Lydia Scarfò
YOU?
Author Swipe
View article: Central Nervous System Involvement in CLL: An International Retrospective Study by ERIC, the European Research Initiative on CLL
Central Nervous System Involvement in CLL: An International Retrospective Study by ERIC, the European Research Initiative on CLL Open
CNS involvement (CNSi) of chronic lymphocytic leukemia (CLL) is a rare condition with no consensus on diagnosis and limited evidence for management and outcome. Here we report an international, multicenter, retrospective study conducted by…
View article: CD19 CAR T‐Cell Therapy in Richter Transformation: A Multicentre Retrospective Analysis by the European Research Initiative on Chronic Lymphocytic Leukaemia
CD19 CAR T‐Cell Therapy in Richter Transformation: A Multicentre Retrospective Analysis by the European Research Initiative on Chronic Lymphocytic Leukaemia Open
Richter transformation (RT) is a serious complication of chronic lymphocytic leukaemia (CLL), with poor outcomes. While CAR T‐cells have shown promise in large B‐cell lymphoma, their efficacy in RT remains unclear, and the role of allogene…
View article: Clinical and transcriptomic characterization of patients with chronic lymphocytic leukemia harboring t(14;19): an ERIC study
Clinical and transcriptomic characterization of patients with chronic lymphocytic leukemia harboring t(14;19): an ERIC study Open
In chronic lymphocytic leukemia (CLL), the role of complex karyotype (CK) for prognostic stratification remains a topic of debate, and the impact of specific cytogenetic abnormalities is still unclear. This study aims to investigate the cl…
View article: Circular RNA signature of aggressive CLL with t(14;19)(q32;q13). An ERIC study
Circular RNA signature of aggressive CLL with t(14;19)(q32;q13). An ERIC study Open
View article: New Horizons in Chronic Lymphocytic Leukaemia : An Interview with Lydia Scarfò
New Horizons in Chronic Lymphocytic Leukaemia : An Interview with Lydia Scarfò Open
View article: A spheroid model that recapitulates the protective role of the lymph node microenvironment and serves as a platform for drug testing in chronic lymphocytic leukemia
A spheroid model that recapitulates the protective role of the lymph node microenvironment and serves as a platform for drug testing in chronic lymphocytic leukemia Open
Chronic lymphocytic leukemia (CLL) B cells are characterized by a propensity to undergo rapid apoptosis when cultured in vitro, underscoring the importance of the tissue microenvironment for disease survival. One of the major limitations i…
View article: Disease-specific U1 spliceosomal RNA mutations in mature B-cell neoplasms
Disease-specific U1 spliceosomal RNA mutations in mature B-cell neoplasms Open
View article: PEDRO: A Peer-to-Peer Support Platform for Adverse Drug Reaction Management in Patients with CLL
PEDRO: A Peer-to-Peer Support Platform for Adverse Drug Reaction Management in Patients with CLL Open
Chronic Lymphocytic Leukemia (CLL) treatment often leads to adverse drug reactions (ADRs) and drug-drug interactions (DDIs), significantly impacting patients’ quality of life (QoL). To address the challenges in managing ADRs/DDIs, the PEDR…
View article: Resistance to targeted therapies in chronic lymphocytic leukemia: Current status and perspectives for clinical and diagnostic practice
Resistance to targeted therapies in chronic lymphocytic leukemia: Current status and perspectives for clinical and diagnostic practice Open
The integration of BTK and BCL2 inhibitors into the treatment of patients with chronic lymphocytic leukemia (CLL) represents a paradigm shift and has led to significant improvements in clinical outcomes, including prolonged survival and en…
View article: 144 | UPDATED EFFICACY/SAFETY OF THE BRUTON TYROSINE KINASE (BTK) DEGRADER BGB‐16673 IN RELAPSED/REFRACTORY (R/R) CLL/SLL: RESULTS FROM THE ONGOING PHASE 1 CaDAnCe‐101 STUDY
144 | UPDATED EFFICACY/SAFETY OF THE BRUTON TYROSINE KINASE (BTK) DEGRADER BGB‐16673 IN RELAPSED/REFRACTORY (R/R) CLL/SLL: RESULTS FROM THE ONGOING PHASE 1 CaDAnCe‐101 STUDY Open
View article: Monoclonal B‐Cell Lymphocytosis: The Silent Clone the Haematologists Should Not Neglect
Monoclonal B‐Cell Lymphocytosis: The Silent Clone the Haematologists Should Not Neglect Open
Monoclonal B‐cell lymphocytosis (MBL) is a hematologic condition defined by the presence of a small clonal B‐cell population in the peripheral blood, without clinical or laboratory evidence of lymphoproliferative disorders. It is classifie…
View article: OT02 | CLL18/MOIRAI TRIAL AIMING TO ESTABLISH MEASUREMENT OF INDIVIDUAL RESIDUAL DISEASE FOR ADJUSTMENT OF TREATMENT DURATION TO IMPROVE OUTCOMES IN TREATMENT‐NAIVE CLL/SLL
OT02 | CLL18/MOIRAI TRIAL AIMING TO ESTABLISH MEASUREMENT OF INDIVIDUAL RESIDUAL DISEASE FOR ADJUSTMENT OF TREATMENT DURATION TO IMPROVE OUTCOMES IN TREATMENT‐NAIVE CLL/SLL Open
View article: Enhancing Healthcare Professionals’ Adherence to the MyPal Project Digital Health Intervention Protocol Through Quick Reference Guides
Enhancing Healthcare Professionals’ Adherence to the MyPal Project Digital Health Intervention Protocol Through Quick Reference Guides Open
Randomized Clinical Trials (RCTs) are widely used to evaluate new interventions, including digital health solutions, but their complexity can burden Healthcare Professionals (HCPs). The MyPal project, part of the Horizon 2020 initiative, a…
View article: Controlled perfusion of a vascularized microenvironment within a 3D printed bioreactor to study leukemia cells trafficking ex-vivo
Controlled perfusion of a vascularized microenvironment within a 3D printed bioreactor to study leukemia cells trafficking ex-vivo Open
Chronic Lymphocytic Leukemia (CLL) is the most common adult leukemia in Western countries, marked by the accumulation of CD5+ B cells in blood and lymphoid tissues. The vascular system plays a critical role, as malignant cells i…
View article: ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarker
ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarker Open
View article: Venetoclax-based regimens in octogenarian patients with CLL: efficacy, safety, and comparison to BTKi in a multicenter cohort
Venetoclax-based regimens in octogenarian patients with CLL: efficacy, safety, and comparison to BTKi in a multicenter cohort Open
Octogenarians represent a significant fraction of patients with chronic lymphocytic leukemia (CLL) but, despite the prevalence of the disease in this age group, limited data are available on the safety and efficacy of novel drugs in this s…
View article: Bcor loss promotes Richter transformation of chronic lymphocytic leukemia associated with Notch1 activation in mice
Bcor loss promotes Richter transformation of chronic lymphocytic leukemia associated with Notch1 activation in mice Open
View article: Loss of CYLD promotes splenic marginal zone lymphoma
Loss of CYLD promotes splenic marginal zone lymphoma Open
Splenic marginal zone lymphoma (SMZL) is a distinct clinical and pathological entity among marginal zone lymphomas. Genetic and microenvironmental factors leading to aberrant activation of the NF‐κB pathway have been implicated in SMZL pat…
View article: Production of AFM wedged cantilevers for stress-relaxation experiments: Uniaxial loading of soft, spherical cells
Production of AFM wedged cantilevers for stress-relaxation experiments: Uniaxial loading of soft, spherical cells Open
The fabrication of wedge-shaped cantilevers for Atomic Force Microscopy (AFM) remains a critical yet challenging task, particularly when precision and efficiency are required. In this study, we present a streamlined protocol for producing …
View article: Acalabrutinib in High‐Risk Chronic Lymphocytic Leukaemia Naïve Patients: An Italian Multicenter Retrospective Observational Real‐Life Experience
Acalabrutinib in High‐Risk Chronic Lymphocytic Leukaemia Naïve Patients: An Italian Multicenter Retrospective Observational Real‐Life Experience Open
View article: Detection of clinically relevant variants in the <i>TP53</i> gene below 10% allelic frequency: A multicenter study by ERIC, the European Research Initiative on CLL
Detection of clinically relevant variants in the <i>TP53</i> gene below 10% allelic frequency: A multicenter study by ERIC, the European Research Initiative on CLL Open
In chronic lymphocytic leukemia, the reliability of next‐generation sequencing (NGS) to detect TP53 variants ≤10% allelic frequency (low‐VAF) is debated. We tested the ability to detect 23 such variants in 41 different laboratories using t…
View article: Kinetics of lymphocytosis in naïve chronic lymphocytic leukemia patients treated with covalent Bruton's tyrosine kinase inhibitors: An Italian multicenter real‐life experience
Kinetics of lymphocytosis in naïve chronic lymphocytic leukemia patients treated with covalent Bruton's tyrosine kinase inhibitors: An Italian multicenter real‐life experience Open
View article: Outcomes and prognostic factors in 3306 patients with relapsed/refractory chronic lymphocytic leukemia treated with ibrutinib outside of clinical trials: A nationwide study
Outcomes and prognostic factors in 3306 patients with relapsed/refractory chronic lymphocytic leukemia treated with ibrutinib outside of clinical trials: A nationwide study Open
We performed a cohort study that included all patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) who received ibrutinib in the Italian National Health Service. With a median follow‐up of 42.2 months (IQR 30.8–54.6 mon…
View article: The non-canonical BAF chromatin remodeling complex is a novel target of spliceosome dysregulation in SF3B1-mutated chronic lymphocytic leukemia
The non-canonical BAF chromatin remodeling complex is a novel target of spliceosome dysregulation in SF3B1-mutated chronic lymphocytic leukemia Open
View article: Therapeutic strategies and treatment sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC, the European Research Initiative on CLL
Therapeutic strategies and treatment sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC, the European Research Initiative on CLL Open
Therapeutic strategies and treatment sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC, the European Research Initiative on CLL
View article: Realizing precision medicine in chronic lymphocytic leukemia: Remaining challenges and potential opportunities
Realizing precision medicine in chronic lymphocytic leukemia: Remaining challenges and potential opportunities Open
Patients with chronic lymphocytic leukemia (CLL) exhibit diverse clinical outcomes. An expanding array of genetic tests is now employed to facilitate the identification of patients with high‐risk disease and inform treatment decisions. The…
View article: Issue Information
Issue Information Open
No abstract is available for this article.
View article: Real-World Outcome of Treatment with Single-Agent Ibrutinib in Italian Patients with Chronic Lymphocytic Leukemia: Final Results of the EVIdeNCE Study
Real-World Outcome of Treatment with Single-Agent Ibrutinib in Italian Patients with Chronic Lymphocytic Leukemia: Final Results of the EVIdeNCE Study Open
Real-world data in clinical practice are needed to confirm the efficacy and safety that ibrutinib has demonstrated in clinical trials of patients with chronic lymphocytic leukemia (CLL). We described the real-world persistence rate, patter…
View article: Disrupting pro-survival and inflammatory pathways with dimethyl fumarate sensitizes chronic lymphocytic leukemia to cell death
Disrupting pro-survival and inflammatory pathways with dimethyl fumarate sensitizes chronic lymphocytic leukemia to cell death Open
Microenvironmental signals strongly influence chronic lymphocytic leukemia (CLL) cells through the activation of distinct membrane receptors, such as B-cell receptors, and inflammatory receptors, such as Toll-like receptors (TLRs). Inflamm…
View article: Additional booster doses in patients with chronic lymphocytic leukemia induce humoral and cellular immune responses to SARS‐CoV‐2 similar to natural infection regardless ongoing treatments: A study by ERIC, the European Research Initiative on CLL
Additional booster doses in patients with chronic lymphocytic leukemia induce humoral and cellular immune responses to SARS‐CoV‐2 similar to natural infection regardless ongoing treatments: A study by ERIC, the European Research Initiative on CLL Open
Profound immune dysregulation and impaired response to the SARS-CoV-2 vaccine put patients with chronic lymphocytic leukemia (CLL) at risk of severe COVID-19. We compared humoral memory and T-cell responses after booster dose vaccination o…